Interview with Science 37 CEO David Coman

Science 37 CEO David Coman

Science 37 is a publicly traded pioneer in decentralized clinical trials, which offers an end-to-end 'operating' system for trial sponsors and CROs. The company leverages its various networks to enable hybrid and fully decentralized trials. The decentralized model also helps foster diversity and inclusion, which has become an important selling point.

I first met David Coman several years ago when he was in charge of strategy and trial oversight at ERT (now Clario). In this podcast, David discusses how he went from advertising and marketing into the life sciences space, and what the future holds for trials.

Health Business Group is a boutique healthcare consulting firm that develops growth strategies for companies like Science 37. Contact us to learn more.